Annual report pursuant to Section 13 and 15(d)

Revenue and Accounts Receivable - Additional Information (Detail)

v3.8.0.1
Revenue and Accounts Receivable - Additional Information (Detail)
$ in Thousands
12 Months Ended
Dec. 31, 2017
USD ($)
client
Dec. 31, 2016
USD ($)
client
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Revenue $ 29,121 $ 27,049
Sites accounted for approximately 10% or more of our revenue (client) | client 1 1
Biopharma Services    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Revenue $ 14,629 $ 15,321
Biopharma Services | Payor | Sales | 10% or More Clinical Revenue    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Percentage of revenue 11.00%  
Customer One | Biopharma Services | Payor | Sales | 10% or More Clinical Revenue    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Percentage of revenue   16.00%
Clinical Testing | Payor | Testing Volume    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Percentage of revenue 38.00% 31.00%
Response Genetics | Biopharma Services    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Revenue $ 2,717